These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 30726142)
41. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility. Weeks A; Cogger S; Clark N Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545 [No Abstract] [Full Text] [Related]
42. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder. Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972 [TBL] [Abstract][Full Text] [Related]
43. Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost? Costa E Silva JA Hum Psychopharmacol; 2004 Jun; 19(4):215-24. PubMed ID: 15181649 [TBL] [Abstract][Full Text] [Related]
44. Agency offers guidance on office-based drug treatment for opioid addiction. Mitka M JAMA; 2003 Feb; 289(6):690. PubMed ID: 12585931 [No Abstract] [Full Text] [Related]
46. New drug buprenorphine can treat patients addicted to heroin or prescription pain medications. Clark HW W V Med J; 2003; 99(1):42. PubMed ID: 12762216 [No Abstract] [Full Text] [Related]
47. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206 [TBL] [Abstract][Full Text] [Related]
48. An integrated program of buprenorphine in the primary care setting for HIV(+) persons in Rhode Island. Mitty J; Macleod C; Loewenthal H; Thompson L; Bazerman L Med Health R I; 2007 May; 90(5):145-7. PubMed ID: 17557657 [No Abstract] [Full Text] [Related]
49. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. Robinson SE CNS Drug Rev; 2002; 8(4):377-90. PubMed ID: 12481193 [TBL] [Abstract][Full Text] [Related]
50. Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment. Raheemullah A; Lembke A JAMA Intern Med; 2019 Mar; 179(3):427-428. PubMed ID: 30640372 [No Abstract] [Full Text] [Related]
51. Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio. Molfenter T; Sherbeck C; Starr S; Kim JS; Zehner M; Quanbeck A; Jacobson N; McCarty D J Addict Med; 2018; 12(2):85-91. PubMed ID: 29176511 [TBL] [Abstract][Full Text] [Related]
53. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Strain EC; Stoller K; Walsh SL; Bigelow GE Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310 [TBL] [Abstract][Full Text] [Related]
54. Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities. Wakeman SE; Barnett ML N Engl J Med; 2018 Jul; 379(1):1-4. PubMed ID: 29972748 [No Abstract] [Full Text] [Related]
55. Enhancing engagement between legislators and nursing to increase buprenorphine access. Finnell DS; Schimmels J; Tierney M Nurs Outlook; 2023; 71(4):102004. PubMed ID: 37429154 [No Abstract] [Full Text] [Related]
56. The alternative therapy. Hicks M Nurs Stand; 2000 Jul 26-Aug 1; 14(45):18. PubMed ID: 11974198 [No Abstract] [Full Text] [Related]
57. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment. Lapeyre-Mestre M Therapie; 2020; 75(5):393-395. PubMed ID: 33039103 [No Abstract] [Full Text] [Related]
58. Buprenorphine: blending practice and research. Ling W; Smith D J Subst Abuse Treat; 2002 Sep; 23(2):87-92. PubMed ID: 12220606 [TBL] [Abstract][Full Text] [Related]
60. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults. Cottrill CB; Matson SC Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]